ECHELON-2

A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222119

Enrollment

452

Registered

2013-06-18

Start date

2013-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD30-positive mature T-cell lymphomas

Interventions

investigational material(s) Generic name etc : brentuximab vedotin INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with newly diagnosed, CD30-positive mature T-cell lymphomas 2) Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT 3) Eastern Cooperative Oncology Group Performance Status less than or equal to 2

Exclusion criteria

Exclusion criteria: 1) History of another primary invasive malignancy that has not been in remission for at least 3 years 2) Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas or mycosis fungoides 3) History of progressive multifocal leukoencephalopathy 4) Cerebral/meningeal disease related to the underlying malignancy

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Overall survival, Objective response rate, Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026